Member Info for jimbobtechstock

The problem FDBK has (apart from ex director having an agenda that appears at odds with LTHs of Feedback) is the legacy of the short-lived DC tenure as CEO. Clearly from the RNS shortly before his departure David Crabb had set his stall out to raise more funds this year, and the market has been expecting that ever since. What we don't know is the effect of DC leaving.

Riddell and Simon Sturge agreed in April to take shares in lieu of fees (see RNS April 16).

" Furthermore, Dr Alastair Riddell and Simon Sturge will receive share options in lieu of fees to reduce board cash costs and a further announcement will be made when such options are granted."

I don't know the details of DC's departure but it came almost exactly 6 months after his appointment. One scenario is that Crabb was negotiating his remuneration after an initial 6-month run-in period, which put him at odds with Riddell and Sturge deciding to take shares and options in lieu of fees?

I know that AR's fees have been a bugbear of one ex director and former large shareholder, or at least he told me that it was a worry. So I had hoped that AR announcing he would no longer be taking substantial fees would have won him round.

Given the market reaction today I'm reasonably confident someone is shorting. What I don't know is whether this is on spec or based on solid knowledge of an imminent fund raise. I personally don't think it's a given, but the agenda-posting on this board by someone with a very nagative view has done its job and left everyone with that lingering doubt, which is often enough to tip sentiment one way.

04-Sep-18 17:07:52 11.90p 3,268,984

FWIW just a small technical trade for me here, the comment below about lower lows is fair enough but not a disaster. I think the bears are trading this assuming HT are selling their 10p shares, which they may or may not have a forward sold some (shorted) against their incoming shares.. But no guarantee the bears have it right either.

RSI oversold, stochs and MACD on the cusp of a bull signal,

Re the lower low, well I actually see a very jagged W1 and W2 formed, which would indicate W3 possible (nothing ever guaranteed) so maybe with a positive trading update (if the much improved website stats posted below are an indication of what's happening to revenue) once the dust settles on the old news and we'll see a decent recovery. Though as per the bear sentiment posted below I'm not expecting miracles overnight.

My W1-2 theory in this tweet https://twitter.com/jimbobtechstock/status/1036605445220302850

Think they'll want to get the results out of the way - the known bad news - before putting out an update about how the funding is working with revenue etc.

Leaky as hell this, as the 1-code blasting late last week and then the huge sell off yesterday.

Though I don't think the numbers warrant a sell off as they are pretty much as trailed, revenue down but cost-cutting has stemmed losses.

Auditors Going Concern section is reassuring. "With the existing funding received the Group has cash resources to support operations for a minimum of 12 months from the date of approval of financial statements, supporting the going concern assumption."

Looks like some may have bought for a bounce on the seller clearing with that large trade, as I did, but have now given up. Maybe the seller still selling. In any case I like the look of this for a long boring hold, only have a small handful but will average down if it becomes clear what has happened. Paying down debt never bad and as I've said a few times on Twitter etc the PnL history is far better than the headline chart shows. Cash management has been pretty good of late and the non-profit years look like genuine exceptional items/1-off costs rather than book fiddling. The underlying revenue and profit trend is OK, for what we know.

Of course it's what we don't know that often bites us but hopefully this little pullback is just the bored being rinsed out of their shares on a company with a genuinely very low free float.

Must be just about getting ready to close up.

Can't believe anyone other than dabblers or distressed sellers are selling down here. Been a major play over the last year on here.

It's Q3 so we get to see latest Lojuxta numbers, either in the interims or in a trading update if they choose to give.

Interim BE readout getting closer

We might hear what they're going to do with AP103.

Plus I still feel there's something going on re AP102, maybe they're going to offload it or go with a JV. Why else rigorously defend your IPR in court like they did (on the QT) in spring this year.

Share price slide has defied the solid progress on fundamentals.

Last trade of 17.2p 09:24 puts BRH at #10 in the list of market decliners on the exchange at the time of the trade. Is there something in those results the market doesn't like? Or are we all being taken for a ride by the traders and MM? Add together the insiders and 3%+ notified holders for BRH and 70% of the shares here are "held" Could that have something to do with it, because the free float is smaller than most?

Found this genuinely interest, Q&A re the interim trial results. Wasn't so sure after the market reaction to the data on Monday but now I'm thinking data looks more promising than I first though, PLUS the market reaction gives a much more attractive entry point today, being some 34% below peak on results day, and financials are now known... https://www.***************************/evgen-pharma-plc-qa-interim-update-stem-clinical-trial-lonevg/412752946 (Link probably won't work due to d i re ct or s ta lk being blocked so can try this) https://goo.gl/xcMyeb

-- "Really can't understand the mentality to buy one day and sell the next on a loss, makes no sense. Has anything changed overnight no" -- Bought yesterday on a knee-jerk, but I did scan the most recent results first. My only concern is that it didn't recover much if any of the initial drop - that could be because the sell and hence drop was for a reason, but also could be traders and MM scrapping over the seeds because they know a fair number of yesterday's buyers can be scared out by holding it a bit longer here. Trend is reasonably flat with a slight dip in gross profit, I have no worries there. But what might be interesting insight is the overall PnL trend my research platform shows up. Over 5 years, Profit(loss) £000 2012: (1,706) [(2,583) inc 1,077 non-cash impairment charge] 2013: (1,155) [(1,257) inc 102 non-cash impairment charge] 2014: (55) 2015: 426 2016: 92 [(2,486) inc (2,578) non-cash impairment charge] 2017: 387 As you might see, taking the PnL trend without taking into account the write-downs, as some might do, leaves a pretty ugly picture of a company see-sawing between thin profit and large loss. As far as I can see from the free cash trend the write-downs genuinely have no underlying impact (apart from building a loss that can be brought-forward to reduce tax) Overall, cash management and in particular debt management, with their use of invoice factoring and the reasonably attractive rates they're managing to get for that facility seem good. Was therefore happy to buy and hold a few on the sub 1p value brought about by the seller, on a PER of around 7.5 from my buy-in. In the absence of any reason for the sell-off emerging current mcap of £3m does seem a bargain for a profitable company with £22m turnover and borrowing level within a quarter of turnover.

Probably worked over the day, could be either way. Decent volume when Nex taken into account. Great consolidation at a resistance/support horizontal. Thought we might just break out in the last 30 minutes as I've seen happen on a few other shares in a surprise Friday afternoon bit of activity but very happy here

Still only providing 5k max per buy quote and live bid is back rising again, recovering after earlier sells. Great bit of consolidation against a rising price.

Judging by the sudden lack of supply (again) I'd say there's yet another one just taken - probably delayed.

Max RSP quote for 5,000 shares only now. 15p is where it was held a few weeks ago when patent news was updated at EPO, also a resistance horizontal. Looks like a bear play to kill momentum by restricting the RSP availability, been a false book here for a few days and the shenanigans hiding 50k buys yesterday behind 1 hour delays adds to my strong suspicions that someone needs shares under 15p and is manipulating the market to make that happen

Probably because the company's major shareholder had a much greater choice of flights from Frankfurt to London than Dublin, saving 30 minutes of flying time too... also Nomad and probably most other major holders had a London base.

Another wildcard could be progress towards launch under existing EMA marketing approval for the conditions listed in the March trading update; plus as well as potential in-licensing a new drug there is a small chance a RoW rights deal might be stuck. There's also possible news on what they're going to do with the new gene therapy platform AP103, as well as my little pet theory that AP102 will be sold on (just a hunch based on it not featuring prominently in this year's annual report - however the recent court action against Dr Harris would suggest AMYT still see value in AP102 else why defend it).

Whistleblowers Stop Off-Label Use of Drug Costing $300,000 Annually https://thewallacelawfirm.com/2017/10/16/whistleblowers-stop-off-label-use-of-drug-costing-300000-annually/ "Three former employees filed suit under the False Claims Act saying that Aegerion Pharmaceuticals, Inc. was encouraging doctors to use a drug called Juxtapid for uses that were not approved by the FDA. It�s a good thing that whistleblowers stopped this one; at $300,000 a year, Juxtapid is one of the most expensive drugs on the market.| "

Anyway the irony here, with all this slurs and aspersions, is that the negative poster below clearly doesn't have the foggiest clue as to /how/ the Aegerion scandal was uncovered. Because it wasn't the patients who complained... Nor was it the outside medical establishments... Nor did the regulators stumble upon something suspicious.... Because if the poster did know how the investigation into Aegerion started he probably wouldn't be so keen to bandy around all these slurs and insinuations.

You're certainly on something. Probably Mark's lawyer using UK libel law with a reverse burden of proof to scare the site into taking it down. Because personally I'd prefer if your baseless slurs stayed up to show how off the mark you are. Assuming from your posting you are US resident, Bronx and Yorkville perhaps you moved from one to the other or live/work commute. You might not be aware of the pretty draconian libel laws we work under, luckily as a US resident (if indeed you are) you are shielded from cases. I've been the target myself, someone didn't like what I posted, a guy was drunk and fed me false information, I posted as much, I got sued... Anyway, the problem with UK libel law is that it's up to the respondent to prove that what he wrote was true or fair comment. All the plaintiff has to do is demonstrate to the court that what was written could cause some reputational damage.

Clarification: The doctor didn't work for Aegerion. The doctor has admitted providing access to his practice record to assist the Aegierion sales team. The fact the Aegerion sales team 'went rogue' has been well known. As far as I can tell the first regulator filing from Aegerion regarding a SEC investigation into the sales and disclosure activities for Juxtapid (the SEC started the ball rolling, rather than the FDA for some reason) was in January 2015. That's nearly 2 years BEFORE Amryt obtained the European sales license for Lojuxta, so I assume sophisticated investors in Amryt would have uncovered the string of bad press re Aegerion in the 2 years following first reports emerging. CEO Marc Beer was under pressure at Aegerion even before the reports of misselling started emerging. He stepped down mid 2015, as did the COO Craig Fraser. Again all happened well before Amryt even completed the RTO (April 2016) never mind acquired Lojuxta (Dec 2016) so to post here as if it should be news to Amryt holders looks rather like a ploy to get something negative onto a board where the company fundamentals are shaping up to be anything but negative. And yes, Amryt employed a medic from Aegerion; but, as I said last time this sludge was posted, the Aegerion miss-selling scandal was just that - a sales issue. Even if it did go all the way to the top there is zero evidence to suggest the Amryt recruit, clinically focussed, was any way involved. Now, I'm sure if Amryt had employed anyone with a background at e.g. GSK we would all be on here suggesting that this person must be involved in some level of bribery, because of course all staff working at a firm charged with any offence are absolutely guilty, both jointly and individually, of that offence, aren't they...

As I remember from the UKIS presentation, reiterated here, the incidence of HoFH is higher across the middle east. 4 new ME distro agreements (on top of the 5 signed over the start of the year): https://www.investegate.co.uk/amryt-pharma-plc--amyt-/rns/four-middle-east-lojuxta--distribution-agreements/201805290700164373P/